Intellia Thera CS (NTLA)

Jan 17, 2025, 12:20 PM EST - 14 hours ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

EDIT

Jan 17, 2025, 10:00 AM EST - 17 hours ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Stockholders to Learn More About the Investigation

Jan 16, 2025, 10:00 AM EST - 1 day ago

Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Investors to Inquire about Securities Investigation

Jan 15, 2025, 10:00 AM EST - 2 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Investors to Reach Out

Jan 14, 2025, 10:00 AM EST - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out

Jan 13, 2025, 1:03 PM EST - 4 days ago

Intellia Therapeutics: Buying The Path To Commercialization

Jan 13, 2025, 11:30 AM EST - 4 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect

Jan 10, 2025, 1:30 PM EST - 7 days ago

Why Is Intellia Therapeutics Stock Trading Lower On Friday?

Jan 9, 2025, 4:00 PM EST - 8 days ago

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

Jan 6, 2025, 7:30 AM EST - 11 days ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 7:30 AM EST - 7 weeks ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Nov 18, 2024, 10:57 PM EST - 2 months ago

Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)

Nov 16, 2024, 10:16 AM EST - 2 months ago

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Nov 11, 2024, 8:30 AM EST - 2 months ago

Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus

Nov 7, 2024, 2:49 PM EST - 2 months ago

Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:30 AM EST - 2 months ago

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Oct 31, 2024, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

Oct 25, 2024, 12:25 PM EDT - 3 months ago

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity

Oct 24, 2024, 1:36 PM EDT - 3 months ago

Intellia Therapeutics, Inc. (NTLA) Call to Discuss NTLA-2002 Phase 2 Study Results Transcript

Oct 24, 2024, 12:43 PM EDT - 3 months ago

Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?

Oct 24, 2024, 8:01 AM EDT - 3 months ago

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Oct 10, 2024, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

Oct 7, 2024, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Oct 6, 2024, 2:00 PM EDT - 3 months ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EDIT EXAS

Oct 1, 2024, 7:30 AM EDT - 3 months ago

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

Sep 25, 2024, 4:40 PM EDT - 4 months ago

Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case

Sep 25, 2024, 12:46 PM EDT - 4 months ago

3 'Repeatable' Biotech Trades

DVAX FOLD GSK XBI

Sep 12, 2024, 7:30 AM EDT - 4 months ago

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

Aug 8, 2024, 11:29 AM EDT - 5 months ago

Intellia Therapeutics, Inc. (NTLA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:30 AM EDT - 5 months ago

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 3, 2024, 6:03 AM EDT - 5 months ago

Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)

Aug 1, 2024, 7:30 AM EDT - 6 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

Jul 30, 2024, 7:30 AM EDT - 6 months ago

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

Jul 8, 2024, 5:11 PM EDT - 6 months ago

BlueAllele Corporation Files Lawsuit for Patent Infringement against Intellia Therapeutics, Inc., for the Unauthorized Use of BlueAllele's Patented Bi-directional Insertion Templates

Jul 2, 2024, 12:53 PM EDT - 7 months ago

Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm

Jun 27, 2024, 4:48 PM EDT - 7 months ago

3 Biotech Stocks For The Second Half Of 2024

ALT MIRM

Jun 26, 2024, 7:30 AM EDT - 7 months ago

Intellia Therapeutics Announces CFO Transition

Jun 25, 2024, 3:30 PM EDT - 7 months ago

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

Jun 24, 2024, 4:51 AM EDT - 7 months ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK ARWR VRNA XFOR

Jun 17, 2024, 7:30 AM EDT - 7 months ago

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024

Jun 14, 2024, 7:30 AM EDT - 7 months ago

Intellia Therapeutics Names Brian Goff to its Board of Directors

Jun 5, 2024, 7:11 AM EDT - 8 months ago

Intellia Therapeutics Presents Promising In Vivo CRISPR Results

Jun 2, 2024, 8:00 AM EDT - 8 months ago

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

May 29, 2024, 2:45 PM EDT - 8 months ago

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

ARVN AXSM CYTK NVS PFE REGN VKTX